Platelet-derived Growth Factor (PDGF) in Cancer

Platelet-Derived Growth Factor Receptor (PDGFR) Kinase Inhibitors

In recent years, several RTK inhibitors with in vivo activity have been developed. Most of these inhibitors have focused on targeting the signaling pathways of VEGF, but diverse chemical compounds were also developed as selective PDGFR kinase inhibitors. Many of these PDGFR kinase inhibitors, including several quinoxalines were found to be highly potent and selective toward the PDGFR and its family members, kit and Flt3.

Inhibition of Platelet-derived Growth Factor Receptor Signaling

Inhibition of the PDGF signal pathway results in loss of pericytes and a reduction in vessel density in the neovascularized cornea that correlates with reduced expression of PDGF, ang1/2, and VEGF mRNA. PI3-K is known to be involved in the regulation of VEGF, ang1, and PDGF, as the PI3-K inhibitors wortmannin or LY294002 has similar effects. Since PDGF is a known stimulus for PI3-K activation, decrease in VEGF, ang1/2, and PDGF mRNA levels on administration of the PDGF inhibitor is caused by the decreased activation of the PI3-K signaling cascade.

Platelet-derived Growth Factor (PDGF) Inhibitor Related Studies

23000+ Products
cDNA Clones
Recombinant Cytokines
PDGF Information
PDGF Receptors
PDGF Inhibitor
PDGF Signaling Pathway
PDGF in Cancer
PDGF Reagents
PDGF Proteins
PDGF Antibodies
PDGF cDNA Clones
All PDGF Products
Growth Factor Family
Ephrin & Eph Receptor
EGF & Receptor
FGF & Receptor
Insulin-like Growth Factor System
Neurotrophin & Receptor
PDGF & Receptor
Receptor Tyrosine Kinase
R-Spondin Protein
VEGF & Receptor
Wnt Ligands & Receptors